Skip to main content
SpringerLink
Log in

Weichteilsarkome

Aktueller Stand der neoadjuvanten Therapie

  • TOPIC 1 • weichteilsarkome
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Weichteilsarkome sind eine heterogene Gruppe bösartiger Tumoren, die insgesamt nur 1% aller malignen Erkrankungen ausmachen [27]. Klassischerweise finden sich ca. 60% der Weichteilsarkome an den Extremitäten mit Prädilektion der unteren Extremität [41]. Die Therapie sollte interdisziplinär erfolgen, wobei die Vorstellung in einem Zentrum mit auf die Therapie von Weichteilsarkomen spezialisierten Chirurgen, Orthopäden, Strahlentherapeuten, Onkologen und Pathologen dringend empfohlen wird.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in highgrade soft-tissue sarcomas. Clin Cancer Res 15(8):2856–2863

    Article  PubMed  CAS  Google Scholar 

  2. Blackmon SH, Shah N, Roth JA et al (2009) Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 88(3):877–884

    Article  PubMed  Google Scholar 

  3. Bonvalot S, Laplanche A, Lejeune F et al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16(7):1061–1068

    Article  PubMed  CAS  Google Scholar 

  4. Bramwell VH, Anderson D, Charette ML (2003) Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev (3):CD003293

  5. Canter RJ, Martinez SR, Tamurian RM et al (2010) Radiographicand histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol 17(10):2578–2584

    Article  PubMed  Google Scholar 

  6. Cormier JN, Pollock RE (2004) Soft tissue sarcomas. CA Cancer J Clin 54(2):94–109

    Article  PubMed  Google Scholar 

  7. Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616–632

    Article  PubMed  Google Scholar 

  8. Davis AM, O'sullivan B, Turcotte R et al (2005) Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 75(1):48–53

    Article  PubMed  Google Scholar 

  9. Wilt JH de, ten Hagen TL, Boeck G de et al (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82(5):1000–1003

    Article  PubMed  Google Scholar 

  10. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al (2010) Impact of dynamic 18 F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 51(4):551–558

    Article  PubMed  Google Scholar 

  11. Dudeck O, Zeile M, Pink D et al (2008) Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 27(5):1109–1113

    Article  PubMed  Google Scholar 

  12. Eggermont AM, Wilt JH de, ten Hagen TL (2003) Current uses of isolated limb perfusion in the clinicand a model system for new strategies. Lancet Oncol 4(7):429–437

    Article  PubMed  Google Scholar 

  13. Eggermont AM, Schraffordt Koops H, Klausner JM et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224(6):756–764

    Article  PubMed  CAS  Google Scholar 

  14. Eggermont AM, Schraffordt Koops H, Lienard D et al (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14(10):2653–2665

    PubMed  CAS  Google Scholar 

  15. Eggermont AM, Schraffordt Koops H, Lienard D et al (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14(10):2653–2665

    PubMed  CAS  Google Scholar 

  16. Folpe AL, Lyles RH, Sprouse JT et al (2000) (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 6(4):1279–1287

    PubMed  CAS  Google Scholar 

  17. Gortzak E, Azzarelli A, Buesa J et al (2001) A randomised phase II study on neo-adjuvant chemotherapy for ‚high-risk ‘adult soft-tissue sarcoma. Eur J Cancer 37(9):1096–1103

    Article  PubMed  CAS  Google Scholar 

  18. Gronchi A, Bui BN, Bonvalot S et al (2011) Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (in press)

  19. Grosso F, Jones RL, Demetri GD et al (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8(7):595–602

    Article  PubMed  CAS  Google Scholar 

  20. Grunhagen DJ, Brunstein F, Graveland WJ et al (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240(6):939–947

    Article  PubMed  Google Scholar 

  21. Grunhagen DJ, Wilt JH de, Graveland WJ et al (2006) Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 106(8):1776–1784

    Article  PubMed  CAS  Google Scholar 

  22. Grunhagen DJ, Wilt JH de, ten Hagen TL, Eggermont AM (2006) Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 3(2):94–103

    Article  PubMed  Google Scholar 

  23. Gutman M, Inbar M, Lev-Shlush D et al (1997) High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation. Cancer 79(6):1129–1137

    Article  PubMed  CAS  Google Scholar 

  24. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J (1987) Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 60(8):1703–1707

    Article  PubMed  CAS  Google Scholar 

  25. Hohenberger P, Haier J, Kettelhack C et al (1997) Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan. Chirurg 68(9):914–920

    Article  PubMed  CAS  Google Scholar 

  26. Italiano A, Delva F, Mathoulin-Pelissier S et al (2010) Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 21(12):2436–2441

    Article  PubMed  CAS  Google Scholar 

  27. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54(1):8–29

    Article  PubMed  Google Scholar 

  28. Koshy M, Rich SE, Mohiuddin MM (2010) Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis. Int J Radiat Oncol Biol Phys 77(1):203–209

    Article  PubMed  Google Scholar 

  29. Krementz ET, Carter RD, Sutherland CM, Hutton I (1977) Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 185(5):555–564

    Article  PubMed  CAS  Google Scholar 

  30. Lans TE, Wilt JH de, Geel AN van, Eggermont AM (2002) Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma. Ann Surg Oncol 9(10):1004–1009

    Article  PubMed  CAS  Google Scholar 

  31. Le Cesne A, Van Glabbeke M, Woll PJ et al (2008) The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]. J Clin Oncol 26(Suppl 15):559

    Google Scholar 

  32. Lejeune FJ, Lienard D, Matter M, Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6

    PubMed  Google Scholar 

  33. Lejeune FJ, Pujol N, Lienard D et al (2000) Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 26(7):669–678

    Article  PubMed  CAS  Google Scholar 

  34. Lev-Chelouche D, Abu-Abeid S, Merimsky O et al (1999) Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Arch Surg 134(2):177–180

    Article  PubMed  CAS  Google Scholar 

  35. Lienard D, Ewalenko P, Delmotte JJ et al (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10(1):52–60

    PubMed  CAS  Google Scholar 

  36. Lienard D, Ewalenko P, Delmotte JJ et al (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10(1):52–60

    PubMed  CAS  Google Scholar 

  37. Meric F, Hess KR, Varma DG et al (2002) Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95(5):1120–1126

    Article  PubMed  Google Scholar 

  38. Noorda EM, Vrouenraets BC, Nieweg OE et al (2003) Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 98(7):1483–1490

    Article  PubMed  CAS  Google Scholar 

  39. O'sullivan B, Davis AM, Turcotte R et al (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359(9325):2235–2241

    Article  PubMed  Google Scholar 

  40. Pervaiz N, Colterjohn N, Farrokhyar F et al (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3):573–581

    Article  PubMed  Google Scholar 

  41. Pisters PW, Leung DH, Woodruff J et al (1996) Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14(5):1679–1689

    PubMed  CAS  Google Scholar 

  42. Potter DA, Kinsella T, Glatstein E et al (1986) High-grade soft tissue sarcomas of the extremities. Cancer 58(1):190–205

    Article  PubMed  CAS  Google Scholar 

  43. Rosenberg SA, Tepper J, Glatstein E et al (1982) The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196(3):305–315

    Article  PubMed  CAS  Google Scholar 

  44. Ruegg C, Yilmaz A, Bieler G et al (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4(4):408–414

    Article  PubMed  CAS  Google Scholar 

  45. Schuetze SM, Baker LH, Benjamin RS, Canetta R (2008) Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 13(Suppl 2):32–40

    Article  PubMed  Google Scholar 

  46. Stam TC, Swaak AJ, Vries MR de et al (2000) Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 7(4):268–275

    Article  PubMed  CAS  Google Scholar 

  47. Steinau HU, Daigeler A, Langer S et al (2010) Limb salvage in malignant tumors. Semin Plast Surg 24(1):18–33

    Article  PubMed  Google Scholar 

  48. Van Glabbeke M, Verweij J, Judson I, Nielson OS (2002) Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (38):543–549

  49. Verma S, Younus J, Haynes AE et al (2008) Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastaticadult soft tissue sarcoma: a clinical practice guideline. Curr Oncol Rep 15(2):80–84

    CAS  Google Scholar 

  50. Wieberdink JBC, Braat RP, Slooten EA van, Olthuis GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905–910

    Article  PubMed  CAS  Google Scholar 

  51. Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905–910

    Article  PubMed  CAS  Google Scholar 

  52. Williard WC, Hajdu SI, Casper ES, Brennan MF (1992) Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 215(3):269–275

    Article  PubMed  CAS  Google Scholar 

  53. Yang JC, Chang AE, Baker AR et al (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16(1):197–203

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hand-, Plastische- und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie der Ruprecht-Karls-Universität Heidelberg, BG-Unfallklinik Ludwigshafen, Ludwigshafen, Deutschland

    M. Lehnhardt & A. Daigeler

  2. Medizinische Klinik V, Abteilung für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    T. Schmitt & G. Egerer

  3. Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    M. Bischof

  4. Klinik für Hand-, Plastische- und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie der Ruprecht-Karls-Universität Heidelberg, BG-Unfallklinik Ludwigshafen, Ludwig-Guttmann-Str. 13, 67071, Ludwigshafen, Deutschland

    M. Lehnhardt

Authors
  1. M. Lehnhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bischof
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Daigeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Egerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Lehnhardt.

Additional information

Dieser Beitrag wurde erstmals publiziert in Der Chirurg 11/2011

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehnhardt, M., Schmitt, T., Bischof, M. et al. Weichteilsarkome. best practice onkologie 7, 4–12 (2012). https://doi.org/10.1007/s11654-012-0419-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-012-0419-9

Search

Navigation